Evidence map›Paper›PMID 39858343›Full record

ReviewAntibiotics (Basel, Switzerland)2025

Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings.

Shyam Kumar Mishra, Tanzina Akter, Umme Laila Urmi, George Enninful, Manjulatha Sara, Jiawei Shen, Dittu Suresh, Liangjun Zheng, Elias Shiferaw Mekonen, Binod Rayamajhee and 3 more

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. The intricacies ofFrontiers in microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shyam Kumar MishraSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-3888-7319
Tanzina AkterSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-2971-9364
Umme Laila UrmiSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-1327-1638
George EnninfulSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-0765-3867
Manjulatha SaraSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-5002-421X
Jiawei ShenSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Dittu SureshSchool of Chemistry, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia.
Liangjun ZhengDepartment of Animal Science and Technology, University of Northwest A&F, Yangling 712100, China.ORCID 0009-0009-3655-8683
Elias Shiferaw MekonenSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Binod RayamajheeSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Francesco M LabricciosaGlobal Alliance for Infections in Surgery, 62100 Macerata, Italy.
Massimo SartelliDepartment of Surgery, Macerata Hospital, 62100 Macerata, Italy.
Mark WillcoxSchool of Optometry and Vision Science, Faculty of Health and Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-3842-7563

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance is a critical global challenge in the 21st century, validating Sir Alexander Fleming's warning about the misuse of antibiotics leading to resistant microbes. With a dwindling arsenal of effective antibiotics, it is imperative to concentrate on alternative antimicrobial strategies. Previous studies have not comprehensively discussed the advantages and limitations of various strategies, including bacteriophage therapy, probiotics, immunotherapies, photodynamic therapy, essential oils, nanoparticles and antimicrobial peptides (AMPs) within a single review. This review addresses that gap by providing an overview of these various non-antibiotic antimicrobial strategies, highlighting their pros and cons, with a particular emphasis on antimicrobial peptides (AMPs). We explore the mechanism of action of AMPs against bacteria, viruses, fungi and parasites. While these peptides hold significant promise, their application in mainstream drug development is hindered by challenges such as low bioavailability and potential toxicity. However, advancements in peptide engineering and chemical modifications offer solutions to enhance their clinical utility. Additionally, this review presents updates on strategies aimed at improving the cost, stability and selective toxicity of AMPs through the development of peptidomimetics. These molecules have demonstrated effective activity against a broad range of pathogens, making them valuable candidates for integration into surface coatings to prevent device-associated infections. Furthermore, we discuss various approaches for attaching and functionalising these peptides on surfaces. Finally, we recommend comprehensive in vivo studies to evaluate the efficacy of AMPs and their mimetics, investigate their synergistic combinations with other molecules and assess their potential as coatings for medical devices.

Indexed as

antimicrobial coatingantimicrobial peptideantimicrobial resistancepeptide engineeringpeptidomimetics

Identifiers

PMID39858343
PMCPMC11762091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.